NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

Ischemic Stroke Clinical Trial

— NICE-MMD  

Official title:

A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04205578
• Other study ID #: KY2019-023
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 2020
• Est. completion date: December 31, 2022

Study information

• Verified date: December 2019
• Source: Beijing Tiantan Hospital
• Contact: Zongze Li, MD
• Phone: 86-13121226581
• Email: lizongze[@]pkuih.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An extracranial-to-intracranial (EC-IC) revascularization is the most widely used treatment to improve cerebral perfusion in patients with moyamoya disease (MMD), and it has been shown to reduce the risk of subsequent stroke and neurological deficit. However, perioperative changes in cerebral hemodynamics can induce fluctuations in cerebral perfusion that may lead to transient or irreversible neurological deficits. Our preliminary single-center study suggests that postoperative intravenous administration of dl-3-n-butylphthalide (NBP) may alleviate perioperative neurological deficits and improve the neurological outcomes after EC-IC revascularization for MMD. This is a multicenter, randomized, double-blind, single-controlled, add-on to standard of care study of NBP in patients with MMD of high risk for ischemic cerebrovascular events after EC-IC revascularization surgery.

Description:

This trial is a prospective, randomized, singe-blinded, placebo parallel controlled, multiple-center trial.

A total of approximately 450 patients (age between18 years and 60 years) with moyamoya disease after EC-IC revascularization will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive butylphthalide in 100 mL of normal saline twice daily since the day of surgery and continued for 14 postoperative days; 2) the other group will receive 100 mL of normal saline twice daily since the day of surgery and continued for 14 postoperative days.

The primary objective is to evaluate the rate and severity of ischemic cerebral event in MMD patients with butylphthalide after EC-IC bypass surgery. The study consists of four visits including the day of randomization(baseline), postoperative day 1 before the first injection, 14 days after surgery when the injection therapy is done, and 30 after suryery. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function scale will be recorded during the program. The rate of stroke event, neurological deficit and severity of neurological deficits will be assessed by modified Rankin scale. The trial is anticipated to last from January 2020 to December 2022 with subjects recruited form two neurosurgical centers in Beijing, China.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 450
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Males or females aged = 18 and = 60 years.

2. Women of childbearing potential (WOCBP) must have a negative urine HCG pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% until the completion of the trial or 60 days after discontinuation of study treatment. Women are considered not childbearing if they are > 1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation). If serum bHCG is the standard of care, then this value can be used to determine eligibility.

3. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.

4. Previous clinical diagnosis of stroke or transient ischemic attack or undiagnosed infarction evidenced on screening CT or MRI

5. Patients with moyamoya disease underwent extra cranial-to-intracranial (EC-IC) bypass surgery, including direct or indirect or combined EC-IC bypass surgery

6. Capable of understanding the purpose and risk of the study and has signed, in writing, the ICF. If the subject is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.

7. Ability to comply with study follow-up.

Exclusion Criteria:

1. Female subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.

2. severely disabled, as defined by a Modified Rankin Scale (mRS) score more than 3.

3. History of intracranial hemorrhage.

4. Postoperative intracranial hemorrhage on CT scan at 4 hours after surgery.

5. Dementia or other progressive neurological disease.

6. Known life expectancy < 6 months (for any reason).

7. Known allergy or hypersensitivity to celery.

8. Received treatment with any other investigational drug within 30 days before baseline, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study.

9. Persons unable or unlikely to return for follow-up visits.

10. Any other reasons that, in the opinion of the investigator, make the subject unsuitable for enrollment.

Related Conditions & MeSH terms

• Cerebral Infarction
• Infarction
• Ischemia
• Ischemic Attack, Transient
• Ischemic Cerebral Infarction
• Ischemic Cerebrovascular Accident
• Ischemic Stroke
• Moyamoya Disease
• Stroke
• Transient Ischemic Attack

Intervention

Drug:
• dl-3-n-butylphthalide (NBP)
25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
• Normal Saline 0.9% Infusion Solution
100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing
China	Peking University International Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
yuanli Zhao	Peking University International Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perioperative ischemic stroke rate	Perioperative cerebral stroke was defined as a symptomatic event of new cerebral infarction within 30 days after surgery and confirmed by CT or MRI. Symptoms included focal neurological deficit or headache lasting more than 24 hours.	within 30 days after surgery
Primary	Perioperative death rate	Rate of perioperative death of any cause within 30 days after surgery	within 30 days after surgery
Primary	Rate of transient neurological deficit (TND)	TND was defined as either any reversible neurological deficits observed objectively (e.g., hemiparesis, dysarthria) or any reversible neurological deficits recognized and reported subjectively (e.g., facial palsy), and without evidence of intracranial hemorrhage and cerebral infarction on images	within 30 days after surgery
Secondary	modified Rankin Scale scores at 30 days after surgery	The modified Rankin Scale scores were recorded at 1 month after surgery.	at 30 days after surgery
Secondary	The severity of transient neurological deficit	The severity of TND was further categorized into four grades based on the clinical symptoms and duration6: Grade 0, none TND; Grade 1, symptoms resolved within 5 days; Grade 2, symptoms prolonged for 5 to 9 days; Grade 3; symptoms prolonged for 10 or more days. One grade worse was scored if there were hemiparesis and/or seizure.	within 30 days after surgery
Secondary	Postoperative intracranial hemorrhagic event	New-onset intracranial hemorrhage within 30 days after surgery and confirmed by CT or MRI.	within 30 days after surgery